

Democratic People's Republic of Korea

Population 2018

26 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	131 (114–149)	513 (446–584)
HIV-positive TB incidence	0.22 (0.12–0.36)	0.87 (0.47–1.4)
MDR/RR-TB incidence ^{oo}	5.2 (2.5–8.8)	20 (10–34)
HIV-negative TB mortality	20 (14–27)	80 (56–107)
HIV-positive TB mortality	0.068 (0.035–0.11)	0.27 (0.14–0.44)

Estimated proportion of TB cases with MDR/RR-TB, 2018	
New cases	2.2%
Previously treated cases	16% (9.1–25)

TB case notifications, 2018	
Total new and relapse	89 939
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	0%
- % pulmonary	80%
- % bacteriologically confirmed ^{ooo}	50%
- % children aged 0-14 years	5%
- % women	34%
- % men	61%
Total cases notified	95 245

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2018	69% (60–79)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	16% (11–21)

TB/HIV care in new and relapse TB patients, 2018		Number	(%)
Patients with known HIV status who are HIV-positive		0	
- on antiretroviral therapy		0	

Drug-resistant TB care, 2018	
% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	
- Previously treated cases	20%
Laboratory-confirmed cases*	MDR/RR-TB: 1 782, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 1 487, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size		Success	Cohort
New and relapse cases registered in 2017		83%	100 553
Previously treated cases, excluding relapse, registered in 2017			
HIV-positive TB cases registered in 2017			
MDR/RR-TB cases started on second-line treatment in 2016		80%	814
XDR-TB cases started on second-line treatment in 2016			

TB preventive treatment, 2018	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100%

TB financing, 2019	
National TB budget (US\$ millions)	50
Funding source: 12% domestic, 14% international, 75% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically